Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C

A Passaro; J Wang; S Shah; J M Bauml; R G Campelo; B C Cho

doi:10.1016/j.annonc.2023.11.012

YUHSpace

BROWSE

0 125

Cited 0 times in

Cited 3 times in

Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C

Authors: A Passaro ; J Wang ; S Shah ; J M Bauml ; R G Campelo ; B C Cho

Citation: ANNALS OF ONCOLOGY, Vol.35(3) : 328-329, 2024-03

Journal Title: ANNALS OF ONCOLOGY

ISSN: 0923-7534

Issue Date: 2024-03

Keywords: Acrylamides* ; Aniline Compounds / therapeutic use ; Antibodies, Bispecific* ; Carcinoma, Non-Small-Cell Lung* / drug therapy ; Carcinoma, Non-Small-Cell Lung* / genetics ; Disease Progression ; ErbB Receptors / genetics ; Humans ; Indoles* ; Lung Neoplasms* / drug therapy ; Lung Neoplasms* / genetics ; Morpholines* ; Mutation ; Protein Kinase Inhibitors / therapeutic use ; Pyrazoles* ; Pyrimidines*

Full Text: https://www.sciencedirect.com/science/article/pii/S0923753423050810

DOI: 10.1016/j.annonc.2023.11.012

Appears in Collections:: 1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

Yonsei Authors: Cho, Byoung Chul(조병철) https://orcid.org/0000-0002-5562-270X

URI: https://ir.ymlib.yonsei.ac.kr/handle/22282913/200572

사서에게 알리기

Show full item record Find it @ YMLIB

License

YUHSpace: Letter to the Editor regarding 'Correspondence to: Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study' by Moik F, Riedl JM, and Ay C

YUHSpace

BROWSE

Browse

Links